Article Menu
Need Help?
No Article Versions Notes Found
Cite
Flume, M.; Bardou, M.; Capri, S.; Sola-Morales, O.; Cunningham, D.; Levin, L.-A.; Touchot, N., on behalf of Payers’ Insight. Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries. J. Mark. Access Health Policy 2016, 4, 30970. https://doi.org/10.3402/jmahp.v4.30970
Flume M, Bardou M, Capri S, Sola-Morales O, Cunningham D, Levin L-A, Touchot N on behalf of Payers’ Insight. Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries. Journal of Market Access & Health Policy. 2016; 4(1):30970. https://doi.org/10.3402/jmahp.v4.30970
Chicago/Turabian StyleFlume, Mathias, Marc Bardou, Stefano Capri, Oriol Sola-Morales, David Cunningham, Lars-Ake Levin, and Nicolas Touchot on behalf of Payers’ Insight. 2016. "Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries" Journal of Market Access & Health Policy 4, no. 1: 30970. https://doi.org/10.3402/jmahp.v4.30970
APA StyleFlume, M., Bardou, M., Capri, S., Sola-Morales, O., Cunningham, D., Levin, L.-A., & Touchot, N., on behalf of Payers’ Insight. (2016). Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries. Journal of Market Access & Health Policy, 4(1), 30970. https://doi.org/10.3402/jmahp.v4.30970
